Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects
暂无分享,去创建一个
D. Montefiori | G. M. Ortiz | D. Nixon | M. Wellons | G. D. Miralles | J. Bartlett | J. Brancato | Hanh Vo | Rebekah Zinn | Daniel E. Clarkson | K. Van Loon | S. Bonhoeffer
[1] G. Shaw,et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.
[2] D. Ho,et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.
[3] K. Harada,et al. Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.
[4] J. Goedert,et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.
[5] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[6] D. Montefiori,et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. , 1996, The Journal of infectious diseases.
[7] D. Montefiori,et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.
[8] E. Rosenberg,et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.
[9] D. Montefiori,et al. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells , 1997, Journal of virology.
[10] C. Rouzioux,et al. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. , 1998, AIDS.
[11] M A Nowak,et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.
[12] C. Sabin,et al. Rebound of HIV-1 viral load after suppression to very low levels. , 1998, AIDS.
[13] V. Calvez,et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. , 1999, AIDS.
[14] M. Plana,et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.
[15] C. Pitcher,et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.
[16] P. Reiss,et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy , 1999, The Lancet.
[17] B. Walker,et al. Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy , 1999, Journal of Virology.
[18] R. Lempicki,et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. Nixon,et al. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. , 1999, The Journal of infectious diseases.
[20] A. Trkola,et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. , 1999, The Journal of clinical investigation.
[21] M. Nowak,et al. Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy , 1999, Journal of Virology.
[22] J. Lisziewicz,et al. Control of HIV despite the discontinuation of antiretroviral therapy. , 1999, The New England journal of medicine.
[23] E. Rosenberg,et al. Association between Virus-Specific Cytotoxic T-Lymphocyte and Helper Responses in Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.
[24] R. Paredes,et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.
[25] D. Nixon,et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. , 2000, The Journal of infectious diseases.
[26] M. Saag,et al. Recurrence of the Acute HIV Syndrome after Interruption of Antiretroviral Therapy in a Patient with Chronic HIV Infection: A Case Report , 2000, Annals of Internal Medicine.
[27] G. M. Ortiz,et al. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. , 2000, The Journal of infectious diseases.
[28] V. Calvez,et al. Dynamics of HIV-Specific CD8+ T Lymphocytes with Changes in Viral Load1 , 2000, The Journal of Immunology.
[29] S. Rowland-Jones,et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection , 2000, AIDS.
[30] E. Rosenberg,et al. Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.
[31] J. Margolick,et al. Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ T-Lymphocyte Reactivity during Combination Antiretroviral Therapy in HIV-1-Infected Patients with Advanced Immunodeficiency , 2000, Journal of Virology.
[32] C. Yoder,et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy , 2000, AIDS.
[33] D. Nixon,et al. Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry. , 2000, AIDS.
[34] C. Yoder,et al. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression , 2000, AIDS.
[35] R. Koup,et al. Putative Immunodominant Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Cannot Be Predicted by Major Histocompatibility Complex Class I Haplotype , 2000, Journal of Virology.
[36] M. Schambelan,et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. , 2000 .
[37] W. Miller,et al. Sex differences in nevirapine rash. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] V. Calvez,et al. Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection , 2001, Journal of Virology.
[39] J. Kahn,et al. Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.